Also trades as: 092730.KS (KSC) · $vol 0M
092730.KQ KOE
NeoPharm Co. Ltd.
1W: -2.3%
1M: -4.9%
3M: +24.9%
YTD: +15.6%
1Y: +22.7%
3Y: +11.4%
5Y: -22.8%
₩23,100.00 ($17.16)
-200.00 (-0.86%)
Weekly Expected Move ±5.0%
₩20781
₩21940
₩23100
₩24260
₩25419
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
Income Trends
Revenue
$132.2B
+11.1% ▲
5Y CAGR: +10.1%
Gross Profit
$84.7B
+14.4% ▲
5Y CAGR: +8.0%
Operating Income
$28.8B
+16.7% ▲
5Y CAGR: +5.6%
Net Income
$27.9B
+21.0% ▲
5Y CAGR: +9.0%
EPS (Diluted)
$1778.81
+20.7% ▲
5Y CAGR: +9.2%
EBITDA
$31.9B
-4.4% ▼
5Y CAGR: +5.5%
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $87.9B | $85.0B | $97.1B | $119.0B | $132.2B |
| YoY Growth | +7.7% | -3.3% | +14.2% | +22.6% | +11.1% |
| Cost of Revenue | $26.6B | $27.8B | $33.0B | $45.0B | $47.5B |
| Gross Profit | $61.3B | $57.3B | $64.2B | $74.0B | $84.7B |
| Gross Margin | 69.7% | 67.4% | 66.1% | 62.2% | 64.1% |
| R&D Expenses | $2.9B | $2.9B | $2.6B | $3.4B | $3.3B |
| SG&A Expenses | $36.0B | $33.0B | $36.3B | $33.5B | $52.6B |
| Operating Expenses | $38.9B | $35.8B | $38.9B | $49.4B | $55.9B |
| Operating Income | $22.4B | $21.4B | $25.3B | $24.7B | $28.8B |
| Operating Margin | 25.5% | 25.2% | 26.1% | 20.7% | 21.8% |
| Interest Expense | $38M | $9M | $21M | $41M | $39M |
| Income Before Tax | $23.8B | $23.3B | $29.4B | $30.2B | $32.3B |
| Tax Expense | $6.1B | $6.3B | $6.2B | $7.1B | $4.4B |
| Net Income | $17.7B | $17.0B | $23.2B | $23.1B | $27.9B |
| Net Margin | 20.1% | 20.0% | 23.9% | 19.4% | 21.1% |
| EPS (Diluted) | $1132.50 | $1088.50 | $1484.00 | $1473.56 | $1778.81 |
| EBITDA | $25.3B | $24.9B | $31.0B | $33.3B | $31.9B |
| Shares Outstanding | 8M | 8M | 8M | 16M | 16M |